ArticleBMC cancer2026
Impact of sarcopenia on short- and long-term outcomes after resection of perihilar cholangiocarcinoma: a two-center study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSarcopenia is associated with poor postoperative outcomes in patients with malignant tumors; however, its impact on perihilar cholangiocarcinoma (pCCA) patients remains unclear. This study aimed to evaluate the predictive value of sarcopenia for postoperative outcomes in patients undergoing resection for pCCA.
methodsA total of 271 patients with perihilar cholangiocarcinoma (pCCA) who underwent surgical intervention between 2016 and 2021 were retrospectively recruited from two institutions. The patients were divided into training and validation cohorts at a 7:3 ratio. Sarcopenia was defined via cutoff values for the skeletal muscle index (SMI) of 52.2 cm²/m² for males and 39.2 cm²/m² for females, which were determined through optimal stratification. Logistic regression and Cox proportional hazards regression were employed to identify significant risk factors associated with postoperative outcomes. Additionally, a novel nomogram based on sarcopenia was developed and subsequently validated via receiver operating characteristic (ROC) curves, calibration curves, and clinical decision curve analysis (DCA).
resultsOf the 271 patients studied, 144 (53.1%) were diagnosed with sarcopenia. Patients with sarcopenia presented significantly higher rates of total complications, major complications, and 90-day readmissions, as well as poorer overall survival (OS), than did those without sarcopenia. multivariable Cox regression analysis revealed several independent risk factors for OS, including body mass index (BMI) (p = 0.026), high performance status (PS) score (p < 0.001), R1 surgical margin (p < 0.001), T stage IV (p < 0.001), COUNT score ≥ 5 (p = 0.005), and the presence of sarcopenia (p < 0.001). A novel nomogram incorporating these six factors was developed to predict OS at 12, 24, and 36 months. The model exhibited robust predictive performance, with a mean area under the curve (AUC) greater than 0.8. The calibration curve closely matched the ideal curve, and decision curve analysis (DCA) further validated the strong predictive ability and substantial positive net benefit of the nomogram.
conclusionSarcopenia is a significant adverse factor for both postoperative complications and long-term survival in patients with pCCA following surgical resection.
Indexed as
Identifiers
42919153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.